New communication on Mablink by Puls@lys

label pulsalys

After having earned the #FrenchTechSeed label in the middle of March, Puls@lys has made an exclusive communication on our Antibody-Drug linker technology as a breakthrough innovation as well as its perspectives in immuno-oncology for the development of next-generation therapeutic molecules.

All Mablink members warmly thank the Puls@lys team and especially Nathaly Mermet for this awesome article.

The complete article in available online on Puls@lys website or downloadable as PDF: Pulsalys-Mablink

Leave a Comment

Your email address will not be published. Required fields are marked *